TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Inclusion Criteria:

• male or female, who is at least 18 years of age or older at the screening visit

• patients with clinical diagnosis of metastatic colorectal carcinoma planned to betreated with cetuximab or panitumumab injections as part of the chemotherapyprotocol

• patients who can understand and sign the Informed Consent Form, can communicate withinvestigator,can understand and comply with requierements of the protocol, and canapply the study gel by himself/herself or have giver who can apply the product

• patients with predicted life expectency of > 3 months

• patients willing and able to comply with all of the time commitements and proceduralrequirements of the clinical trial protocol

Exclusion Criteria:

• patients with medical history of EGFR treatment in the past 2 years

• patients with any underlying physical ,psychological or medical condition that, inthe opinion of the invstigator, would make it unlikely that the patient will complywith the protocol or complete the study protocol

• patients with any uncotrolled or serious disease, or any medical or surgicalcondition,that may put the subject at significant risk (according to theinvestigator's judgement) if he/she participates in the clinical trial

• patients with history of other skin disorders (eg.atopicdermatitis,psoriasis,recurrent skin infections), or a history of illness that, inthe opinion of the investigator, would confound the results of the study

• patients with significant skin disease other than EGFRi-induced folliculits withinthe same body areas planned for study drug application

• patients with a beard that would interfere with administration of the study drug andassessement of study endpoints

• patients with active infection within the treatment area ot in other body areas thatrequieres initiation of systemic antibiotics

• patients with known or suspected allergies or sensitivities to any components of thestudy drugs

• female patients who are pregnant or lactating